Cipla's revenue share 2024, by medical therapy

Published by A. Minhas, Aug 30, 2024

Cipla Limited in India has been known for its generic drugs, of which the gastrointestinal drugs made up the largest share of its total revenue with 23 percent of contribution in fiscal year 2024. This was followed by the company's respiratory drugs and central nervous system drugs with about 18 and 14 percent share of the revenue respectively.

Revenue share of Cipla Limited in financial year 2024, by medical therapy

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

July 2024

Region

India

Survey time period

FY 2024

Supplementary notes

India's financial year begins in April and ends in March. For example, FY 2020 started in April 2019 and ended in March 2020.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharmaceutical industry in China "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical industry in China

Key Figures

7

Drug evaluation and approval

8

Sales channels

7

Pharmaceutical enterprises

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical industry in ChinaCoronavirus COVID-19 in ChinaPharmaceutical industry in JapanVaccine industry in ChinaPharmaceuticals in India
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.